Differentiation of neuropsychological features between posterior cortical atrophy and early onset Alzheimer’s disease

Jieying Li¹,7, Liyong Wu¹, Yi Tang¹, Aihong Zhou¹, Fen Wang¹, Yi Xing¹ and Jianping Jia¹,2,3,4,5,6*

Abstract

Background: Posterior cortical atrophy (PCA) is a group of clinical syndromes characterized by visuospatial and visuoperceptual impairment, with memory relatively preserved. Although PCA is pathologically almost identical to Alzheimer’s disease (AD), they have different cognitive features. Those differences have only rarely been reported in any Chinese population. The purpose of the study is to establish neuropsychological tests that distinguish the clinical features of PCA from early onset AD (EOAD).

Methods: Twenty-one PCA patients, 20 EOAD patients, and 20 healthy controls participated in this study. Patients had disease duration of ≤4 years. All participants completed a series of neuropsychological tests to evaluate their visuospatial, visuoperceptual, visuo-constructive, language, executive function, memory, calculation, writing, and reading abilities. The cognitive features of PCA and EOAD were compared.

Results: All the neuropsychological test scores showed that both the PCA and EOAD patients were significantly more impaired than people in the control group. However, PCA patients were significantly more impaired than EOAD patients in visuospatial, visuoperceptual, and visuo-constructive function, as well as in handwriting, and reading Chinese characters.

Conclusions: The profile of neuropsychological test results highlights cognitive features that differ between PCA and EOAD. One surprising result is that the two syndromes could be distinguished by patients’ ability to read and write Chinese characters. Tests based on these characteristics could therefore form a brief PCA neuropsychological examination that would improve the diagnosis of PCA.

Keywords: Posterior cortical atrophy, Early onset Alzheimer’s disease, Cognition, Neuropsychology

Background

Posterior cortical atrophy (PCA) is manifested mainly as early visual dysfunction in the context of neurodegeneration of posterior cortical regions. Benson [1] first described this syndrome and proposed that it be independently classified. The main clinical features, besides space perception (visuospatial) and object perception (visuoperceptual) deficits, include alexia, Balint syndrome (simultanagnosia, ocular apraxia, and visual ataxia), Gerstmann’s syndrome (acalculia, agraphia, digital agnosia, and left and right confusion), with relative preservation of memory and insight [2]. PCA usually occurs from the mid-50s to early 60s and may account for 5 to 10% of cases diagnosed as early-onset Alzheimer’s disease (EOAD) [3].

Neuropathological studies have indicated demonstrated that most cases of PCA are identical to Alzheimer’s disease [4–6]. In some rare instances, corticobasal degeneration, Lewy bodies dementia and prion disease cause PCA [4, 5]. In cases of Alzheimer’s disease pathology, PCA has also been recognized and described in consensus criteria for atypical Alzheimer’s disease [7], as well as a “visual variant of Alzheimer’s disease” [8]. For a clearer understanding of the pathogenesis in AD, it is crucial to distinguish the
cognitive features of PCA from those of AD. Moreover, with the multiple pathologies that underlie the PCA syndrome [5], pharmacological treatment and behavioral interventions for PCA may differ from those of AD.

Several studies have evaluated clinical differences between PCA and AD, listing core clinical and cognitive features for PCA [4, 6, 9–11]. PCA also has significant features in the form of visuospatial and visuospatial symptoms. However, there are some inconsistencies exist among the cognitive features described in previous studies. Mendes et al. [6] found that verbal fluency was untouched by PCA, but Tang-wai et al. [4] did not. Charles and Hillis [9] and McMonagle et al. [10] found the visual constructional ability of PCA patients was significantly more impaired than in typical AD, which contradicted findings by Mendes. McMonagle et al. [10] and Kas et al. [11], unlike other research teams, found working memory to be more prominently impaired in PCA than in AD.

The origins of the discrepancies in these findings may lie in the use of different neuropsychological tests, different research contexts, different populations, or differences in the duration of disease. Past studies have generally not included information regarding the pathology underlying PCA. This has had several consequences. First, clear differentiation of PCA from EOAD might benefit from the application of a broader set of neuropsychological measures. Second, verification of pathology is necessary to validate neuropsychological differences. That verification is particularly important, because cognitive testing may be more readily available and less expensive than other diagnostic techniques (e.g., PET imaging). The use of these neuropsychological indicators may be efficacious in the diagnosis of PCA, particularly early diagnosis.

The five studies that we found were all performed on Euro-American participants, and it seems feasible that cultural differences may affect the manifestations of PCA. China, with its own cultural characteristics, has a population estimated at more than 1.4 billion people, a substantial proportion of whom fall into the age group most likely to be affected by PCA and EOAD. For this reason, it is important, as both a practical medical concern and a potentially valuable theoretical perspective, to examine neuropsychological factors in Chinese PCA and EOAD patients. We further note that many Chinese people may have limited access to or limited ability to afford sophisticated diagnostic techniques (e.g., imaging), so a quick preliminary screening process would be beneficial.

For this reason, we compared cognitive manifestations of PCA and EOAD in Chinese patients during early stages of the disease. We used a series of neuropsychological tests to identify cognitive features of PCA that distinguish it from EOAD.

### Methods

#### Participants

We recruited patients from the Department of Neurology at Xuan Wu Hospital, Capital Medical University, Beijing, from 2013 to 2016. Healthy controls came from the physical examination center at the same hospital. The clinical sample included 21 PCA and 20 EOAD patients. Patients with PCA met the standard clinical criteria for PCA developed by the AAIC International Working Group [12]. Core clinical features included insidious onset and gradual progression; prominent visuospatial and visuospatial impairments without significant impairment of vision itself; evidence of complex visual disorders (e.g., elements of Balint’s syndrome or Gerstmann’s syndrome, visual field defects, visual agnosia, environmental disorientation); relative preservation of memory and insight; and absence of stroke or tumor. Supportive features included presenile onset, alexia, ideomotor, or dressing apraxia, prosopagnosia, and prolonged color after-images. Structural neuroimaging with either MRI or CT showed pronounced atrophy of the parietotemporo-occipital cortex, and 18F-fluoro-deoxyglucose (FDG) PET or single photon emission computed tomography (SPECT) showed hypometabolism or hypoperfusion in the occipital and parietal lobes. We excluded patients who had a clear history of vascular disease, severe white matter lesions, Lewy body dementia, corticobasal degeneration, frontotemporal dementia, primary progressive aphasia, hydrocephalus, premorbid dyslexia or dysgraphia, or other acute neurological diseases. We also excluded patients with non-AD pathology by brain amyloid imaging. All patients were clinically followed up for at least 12 months to support the diagnosis of PCA.

Patients with EOAD met the IWG-2 diagnostic criteria [7] and exhibited symptom onset prior to age 65. We excluded patients with a history of stroke, traumatic brain injury, chronic alcoholism, or vascular dementia. We recruited the patients who had PCA and EOAD for ≤4 years. We defined disease duration as the time from the onset of the first symptoms observed by the patients themselves or by caregivers at the time the medical records started.

We recruited 20 healthy controls from the physical examination center of Xuan Wu Hospital, Capital Medical University. Participants met the following criteria: no memory complaints; cognitively normal, based on the absence of significant impairment in cognitive functions or activities of daily living (ADL); Clinical Dementia Rating (CDR) = 0; and Mini-Mental State Examination (MMSE) > 26; they had sufficient visual and auditory acuity to allow cognitive testing. Participants with any significant neurologic disease, psychiatric disorders, or psychotic features were excluded.
All the patients completed imaging including brain MRI or CT, and FDG-PET or SPECT. Twelve PCA patients and 20 EOAD patients completed \[^{11}C\]-labeled Pittsburgh compound B (PIB) PET. The method of data processing was described in previous study \[^{13}\]. Positive PIB PET results were recorded for 9 of 12 PCA cases and all EOAD patients and negative results indicative of non-AD pathology in 3 of the 12 PCA patients. We excluded 3 non-AD pathology PCA cases. Nine PCA patients refused to undergo PIB PET due to the high cost of PET (approximately US$ 900, and not covered by insurance). However, we followed up those patients for at least 12 months to exclude Lewy body dementia, corticobasal degeneration, and prion disease; consequently, even in the absence of the PET scan, we were confident of the PCA diagnosis. This study was approved by the Ethics Committee of Xuan Wu Hospital of Capital Medical University. We obtained written informed consent from each participant or caregiver.

**Neuropsychological tests**

All participants completed a battery of neuropsychological assessment measures, including the following: (1) Global cognitive function was assessed using several tests: the Mini-Mental State Examination (MMSE) \[^{14}\]; the Montreal Cognitive Assessment (MoCA) \[^{15}\]; and the Clinical Dementia Rating (CDR) \[^{16}\]. The MMSE cutoff value for normal Chinese populations is ≥26, with education ≤12 years. The MoCA cutoff value for normal Chinese populations is ≥24, with education ≤12 years. (2) Episodic memory was assessed using the World Health Organization University of California-Los Angeles Auditory Verbal Learning Test (AVLT) \[^{17}\], including the AVLT-immediate, AVLT-delay, AVLT-clue, and AVLT-recognized. The cutoff score for immediate recall is ≥18; the delayed recall cutoff score is ≥6. (4) Language was assessed using the Boston Naming Test, BNT \[^{18}\], and verbal fluency (naming as many animals as possible in 1 min). (5) Visuo-constructive function was assessed using the Rey-Osterrich complex figures test of direct copying \[^{19}\] (using 36-point scoring). (6) Attention and working memory were assessed using forward and backward digit span subtests from Wechsler Adult Intelligence Scale \[^{20}\]. (7) Executive function was assessed using the Trail Making Test Parts A and B \[^{21}\]. (8) Mental calculation was assessed using the calculation subtest from the MMSE (Series of Seven Subtraction Test, SSST), and unit conversion (e.g., how many Fens (cents) in one Yuan (dollar)). (9) Writing was assessed by spontaneous handwriting and copying a short sentence from the Aphasia Battery of Chinese \[^{22}\]. Performance was scored by number of words written correctly. (10) Reading was assessed by reading a short sentence, and six lines of text (a total of 118 individual words) selected from a news report. Words were in black Songti font, size 16, presented on a white background. Participants were given a maximum of 300 s to read each passage. For each word, participants who took more than 10 s to respond were prompted to move onto the next word. Participants were not discouraged from using their finger to maintain their place when reading. We used the method developed by Yong KX et al. \[^{23, 24}\]. Performance was scored by number of words correctly read, regardless of word order. Lines skipped and word misread or repeated were also recorded. (11) Visual-spatial function was assessed by tests of bell cancellation \[^{25}\] (total number of omissions is 35; performance was scored as the actual number of bells omitted), the five series of overlapping figure \[^{26}\] (recognize each single object from four overlapping figures), and Navon figures \[^{27}\] (12 Navon figures consisting of a large character (the global level) made out of small characters (the local level)). (12) Visual-perceptual functioning was assessed using a matching test (five objects function matching, and five shapes matching), and the Cookie Theft pictures from the Boston Diagnostic Aphasia Examination \[^{28}\]. PCA patients also underwent the posterior neuropsychological battery, developed by Kas et al. \[^{11}\]. That battery included assessment of Balint’s syndrome, Gerstmann’s syndrome, visual neglect, visual agnosia, limb apraxia, and agraphia.

All participants underwent the neuropsychological assessment on the day of the MRI scan and all were evaluated by the same neuropsychologist, who was blind to the participants’ diagnoses. The battery of neuropsychological tests took 2–3 h. PCA patients were given a half hour to rest between the two batteries of tests.

**Statistical analysis**

Differences between the groups on the neuropsychological tests scores were assessed with one-way ANOVA followed by pairwise comparisons performed with Bonferroni tests, or Kruskal-Wallis H tests followed by the post-hoc tests with pairwise comparisons for test scores that showed deviations from the non-normal distribution. The statistical analysis software reported p values that had been adjusted for the multiple pairwise comparisons between the three groups. The duration of the disease was analyzed using the Mann-Whitney test.

**Results**

**Demographic and clinical characteristics**

We collected demographic data and medical histories from the patients themselves or from their caregivers. Tables 1 and 2 summarize group demographic and clinical characteristics. There was no significant difference in age, sex, or education among the three groups. Also,
there was no significant difference in the disease duration ($p = .602$) between PCA and EOAD patients (Table 1).

**Clinical characteristics of PCA patients**

Clinical characteristics of PCA patients were found to be consistent with the core features of PCA (Table 2). Sixteen patients (89%) presented with simultanagnosia. Seventeen patients (84%) had incomplete Gerstmann’s syndrome. All 18 PCA patients presented with visuo-constructive apraxia, and 17 patients (84%) had concurrent varying degrees of alexia. Sixteen patients (89%) showed memory impairment. Other features included object agnosia (17%), prosopagnosia (11%), abnormal color perception (6%), hemineglect (44%), and limb apraxia (67%).

**Comparison of PCA and EOAD on neuropsychological tests**

Table 3 and Fig. 1 summarize group performances on the neuropsychological tests we administered. Scores on all of the neuropsychological tests showed that both the PCA and EOAD patients were significantly more impaired than in the control group (all $p < 0.05$). The PCA patients exhibited significantly worse performance than EOAD patients in the Rey-Osterreith complex figures tests ($p = .011$). All of PCA patients scored under the cutoff scores in Rey-Osterreith complex figure copy.

Language abilities differed between PCA and EOAD patients. The ability of PCA patients to write was significantly more impaired than in EOAD patients ($p = .002$). PCA patients showed pronounced incomplete words ($n = 12$), word substitution ($n = 7$), unintelligible characters ($n = 11$), character structure impairment ($n = 16$), picture drawing ($n = 5$) with respect to writing Chinese characters. For example, if the direction of stroke was not horizontal or vertical, the stroke was not completed, the enclosed structure was not closed, or a compound character was separated into two or three parts, the character was considered structurally impaired (Fig. 2). Some scripts are appeared scribbled ($n = 16$) and worse than

### Table 1

Demographic data for patients diagnosed with posterior cortical atrophy (PCA) and early onset Alzheimer’s disease (EOAD). Controls were healthy adults with no apparent brain pathology.

| Sample characteristics | PCA ($n = 18$) | EOAD ($n = 20$) | Controls ($n = 20$) | $p$  |
|------------------------|---------------|----------------|-------------------|-----|
| Female/male            | 10/8          | 12/8           | 12/8              | .669a |
| Age (SD), years        | 57.5 (6.1)    | 52.5 (7.3)     | 52.5 (7.7)        | .054b |
| Disease duration (SD), years | 3 (2)        | 3 (1.8)        | –                 | .602c |
| Education (SD), years  | 10.2 (3.7)    | 10.7 (4.5)     | 12.4 (4.1)        | .235b |
| PIB-PET (+/-) ($n = 9$) | 9/0           | 20/0           | –                 |     |

Note: Age, disease duration, and education did not differ significantly among the three groups:
+ , positive PIB PET scan; –, negative PIB PET scan

*aChi-square test
bOne-way ANOVA
cMann-Whitney test
d9 of the PCA patients refused the PIB-PET scan

### Table 2

Visual characteristics of individual patients diagnosed with posterior cortical atrophy (PCA; $n = 18$)

| Symptom                  | Patients Number |
|--------------------------|-----------------|
|                          | 1   | 2   | 3   | 4   | 5   | 6   | 7   | 8   | 9   | 10  | 11  | 12  | 13  | 14  | 15  | 16  | 17  | 18  |
| Visual agnosia           | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   |
| Object agnosia           | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   |
| Prosopagnosia            | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   |
| Color agnosia            | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   |
| Balint’s syndrome        | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   |
| Simultanagnosia          | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   |
| Ocular apraxia           | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   |
| Optic ataxia             | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   |
| Gerstmann’s syndrome     | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   |
| Right-left indistinction | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   |
| Agraphia                 | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   |
| Finger agnosia           | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   |
| Acalculia                | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   |
| Hemineglect              | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   |
| Limb apraxia             | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   |
| Visuo-constructive apraxia| +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   |
| Alexia                   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   |

The plus signs indicate the presence of symptoms.
previous scripts. PCA patients showed significantly more impaired reading ability than EOAD patients \((p = .002)\), manifesting as missed words \((n = 17)\), skipped lines \((n = 14)\), misreading \((n = 10)\), repeated reads \((n = 4)\), and failure to recognize Chinese characters \((n = 7)\). Moreover, PCA patients performed worse than EOAD patients in the bell cancellation task \((p = .018)\), overlapping figures \((p = .002)\), Navon figures \((p = .001)\), and matching test \((p = .004)\), as well as the Cookie Theft picture \((p = .044)\). There were no significant differences between PCA and EOAD patients in AVLT, digit span, trail making, BNT, verbal fluency, calculation, MMSE, MOCA, or CDR scores.

**Discussion**

We compared the cognitive manifestations between PCA and EOAD in Chinese patients. All patients had disease durations under 4 years. The results showed PCA patients to have greater impairment on visuospatial and visuoperceptual tests than EOAD patients, while PCA patients were significantly impaired in Rey-Osterreith complex figure copying, writing, and reading tests, with symptoms of visuo-constructive agnosia, alexia, and agraphia. However, both PCA and EOAD patients had impairments of calculation, episodic memory, working memory, executive function, picture naming, and verbal fluency in the present study. The difference

| Table 3 | Neuropsychological test scores for samples of patients diagnosed with posterior cortical atrophy (PCA; \(n = 18\)) and early onset Alzheimer’s disease (EOAD; \(n = 20\)) |
|------------------|-----------------|-----------------|-----------------|
| Neropsychological tests | PCA | EOAD | \(P\) value |
| MMSE score (30) | 14 (8.8) | 13 (9) | > 1.000a |
| MoCA score (30) | 9.8 (5.7) | 11.3 (5.9) | > 1.000b |
| CDR - SOB (18) | 6 (5.1) | 6.5 (4.5) | > 1.000a |
| **Attention & working memory** | | | | |
| Digit span forward (11) | 7 (1.5) | 7 (2) | > 1.000a |
| Digit span backward (9) | 3 (1) | 3 (1) | .898a |
| **Executive function** | | | | |
| Trail Making Test A Score (24) | 0 (11) | 17.5 (24) | .087a |
| Trail Making Test B Score (24) | 0 (0) | 0 (10.5) | .794a |
| **Language** | | | | |
| Boston naming test (30) | 13.5 (12.8) | 17 (10.5) | .375a |
| Verbal fluency | 9.6 (3.6) | 8.9 (3.3) | > 1.000b |
| **Visuo-constructive function** | | | | |
| Rey-Osterreith complex figure copy (36) | 3.5 (4.6) | 17.8 (16.9) | .011a |
| **Memory** | | | | |
| AVLT-immediate (45) | 11.6 (5.3) | 11.6 (7.0) | > 1.000b |
| AVLT-delay (15) | 0 (2.3) | 0 (1) | > 1.000a |
| AVLT-clue (15) | 2 (3) | 3 (5.5) | > 1.000a |
| AVLT-recognized (15) | 2.5 (4.3) | 3.5 (5.5) | > 1.000a |
| Calculation (8) | 0.5 (2) | 2 (3.75) | .141a |
| Writing test (21) | 1.5 (15.5) | 21 (6.5) | .002a |
| Reading test (19) | 13.3 (8.2) | 19 (3.5) | .002a |
| **Visual-spatial** | | | | |
| Bell cancellation (35) | 7 (10) | 19.5 (22.5) | .018a |
| Overlapping figure (20) | 6.5 (6.3) | 16.5 (5) | .002a |
| Navon figure (12) | 5.5 (7.3) | 12 (2) | .001a |
| **Visual-perceptual** | | | | |
| Matching test (10) | 7 (3) | 10 (2.75) | .004a |
| Cookie theft picture (15) | 7.5 (6.5) | 9.5 (4) | .044a |

Data are shown as median (IQR) or mean (SD). Numbers in parentheses next to the test name are maximum possible scores. MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; CDR-SOB, Clinical Dementia Rating-Sum of Box; AVLT, Auditory Verbal Learning Test

\(\text{aKruskal-Wallis one-way ANOVA followed by post-hoc test}\)

\(\text{bANOVA followed by Bonferroni test}\)
in PCA and EOAD in cognitive features could help the differentiation in clinical diagnosis during early stages of the disease.

PCA patients had more severe symptoms visuospatial and visuoperceptual symptoms than EOAD patients. These results are consistent with earlier reports [2, 11, 29]. Visuospatial and visuoperceptual dysfunction arises from dysfunction of the dorsal streams (occipito-parietal pathway) and the ventral streams (occipito-temporal pathway) [30]. These higher visual dysfunctions are core clinical and cognitive features that define the PCA syndrome. However, PCA lacks standard neuropsychology test profiles for diagnosis or further clinical trials. These cognitive tests evaluating visual function may become a
very quick-acting tool that could be used to distinguish PCA from EOAD.

We found that a significantly higher proportion of PCA patients scored lower than EOAD patients in figure copying tests. Figure copying is mainly related to visuo-constructive function, spatial processing, and visual neglect in bilateral parietal occipital lobe function [31, 32]. The figure copying deficit in our patients may be associated with dorsal stream lesioning [30]. Our findings confirm the results obtained in a previous study [9], which revealed that visuo-constructive impairment is more prominent in PCA patients than in EOAD patients. Our results also indicate that no patients with PCA had normal scores in Rey-Osterreith complex figure copying task, indicating the visuo-constructive function distortion. This test of Rey-Osterreith complex figure copying has been reported to have a 100% sensitivity and specificity with respect to distinguishing PCA from typical AD [9].

PCA patients were more impaired in writing tests than EOAD patients, suggesting that agraphia is an important cognitive feature of PCA. The impairment manifested in the form of incomplete word (stroke omissions and iteration), word substitution, and unintelligible words. The first row is the sample to be copied; the second row is the copy produced by Patient 1; and the third row is the copy produced by Patient 15.

Fig. 2 Examples of handwriting from two PCA patients. Chinese characters are abnormally formed with stroke omissions, word substitution, and unintelligible words. The first row is the sample to be copied; the second row is the copy produced by Patient 1; and the third row is the copy produced by Patient 15.
Chinese system. The visual dysfunction disrupted the conversion of the visual word form to the orthographic, which may leads to pure alexia in Chinese PCA patients [43]. In the future, we plan to investigate the relationship between the visual form processing of Chinese characters and the ability in PCA patients to read as an indicator for pathogenesis of alexia.

We found episodic memory impairment in both PCA and EOAD patients during the early stages of the disease, as indicated by AVLT, but the two conditions did not differ from one another. Memory impairment may therefore be expected to yield poor results when used to distinguish PCA from EOAD. Our results are consistent with those of Charles and Hillis [9] and Ahmed et al. [44], who found memory to be impaired in both PCA and typical AD patients. Kas et al. [11], however, found that PCA patients performed better than typical AD patients on an episodic memory test, even during the early stages of PCA (≤ 3 years since onset). Additionally, the diagnostic criteria for PCA suggest that episodic memory is relatively preserved. This discrepancy in the research literature may be due to different durations of disease, different sample sizes, different memory tests, or some combination of those elements. Because reliability of results depends on the accuracy of diagnosis, our entire sample of PCA patients underwent imaging (FDG PET or SPECT) to ensure sufficient accuracy. In PET amyloid imaging, the majority of our PCA patients had AD pathology with elevated beta-amyloid deposition and diffusion in the cortex. These common pathological bases suggest a reason that both PCA and AD have memory impairment [44].

Despite the evident contrasts between PCA and EOAD patients in the present research, we urge caution in the interpretation of our results. The sample sizes were relatively small, which was unavoidable, owing to the relative rarity of PCA and the difficulties in recruiting participants during the early stage of symptom onset. As result of the small samples involved, it is possible that true differences exist between the PCA and EOAD groups, but that we did not find such differences because the small sample sizes give the experiment limited statistical power. However, we also emphasize that, along with meeting clinical criteria, neuroimaging verified that all our PCA patients had been accurately diagnosed. Most of the PCA patients also underwent PIB-PET to confirm diagnosis by AD pathology. Although nine PCA patients lacked pathological results, for minimize confounding and bias, we followed up those patients for at least 12 months to support AD diagnosis by excluding Lewy body disease, corticobasal degeneration, or prion disease. The PCA and EOAD groups were also matched for disease duration, which may have minimized the clinical differences between PCA and EOAD. Another constraint of our study is neuropsychology measures. Some neuropsychology measures (e.g., SSST, reading and writing tests) were brief and quick for practitioner, but they may result in underestimation of the extent of impairment, and result in ceiling effects in our data (e.g., a bunching of scores at the upper level in control group). Ceiling effects would also tend to obscure true differences between groups. In the future, our studies will systematically examine participants using neuropsychological tests on calculation, reading ability, and writing ability in PCA.

Conclusion
PCA patients present significant cognitive impairments including visuospatial, visuoperceptual, visuo-constructive, writing, and reading. As a diagnostic battery, those tests could be used to reliably distinguish PCA from EOAD. Tests of handwriting and reading appear to have a particularly high specificity for identifying PCA in Chinese-speaking patients. It would be practical to incorporate this battery of tests into existing cognitive screening for PCA, and it could be used to establish a brief and routine PCA neuropsychological examination for improving the early diagnosis of PCA.

Abbreviations
AD: Alzheimer’s disease; ADL: Activities of daily living; AVLT: Auditory verbal learning test; BNT: Boston Naming Test; CDR: Clinical dementia rating; CT: Computed tomography; EOAD: Early-onset Alzheimer’s disease; FDG: 18F-fluoro-deoxyglucose; IWG: International Working Group; MMSE: Mini-Mental State Examination; MoCA: Montreal Cognitive Assessment; MRI: Magnetic resonance imaging; PCA: Posterior cortical atrophy; PET: Positron emission tomography; PIB: [11C]-labeled Pittsburgh compound B; SSST: Single photon emission computed tomography; SSST: Series of Seven Subtraction Test

Acknowledgments
The authors wish to thank the patients and their caregivers for their time and commitment to this research. The authors also want to thank Dr. Fang-Yu Li who provided advice regarding statistical analysis, and Dr. Li-Ping Fu who carried out the PIB-PET acquisition, data analysis, and interpretation.

Funding
This study was supported by the Key Project of the National Natural Science Foundation of China (81530036); the National Key Scientific Instrument and Equipment Development Project (31627803); Mission Program of Beijing Municipal Administration of Hospitals (SML20150801); Beijing Scholars Program, and Beijing Brain Initiative from Beijing Municipal Science & Technology Commission (Z16110000216137); CHINA-CANADA Joint Initiative on Alzheimer’s Disease and Related Disorders (81261120571); Beijing Municipal Commission of Health and Family Planning (PXH2017_026283, 000002); Guiyang Science and Technology Program (2016003).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Authors’ contributions
The work presented here was carried out in collaboration between all authors. JJ conceived and designed the study, LJ drafted the manuscript and performed the statistical analysis. WL, TY, ZA, and WF participated in the clinical evaluation of the patients. XY carried out the neuropsychological evaluation. WL helped draft the manuscript and revise it critically for important intellectual content. JJ reviewed and edited the manuscript. All authors read and approved the manuscript.
Ethical approval and consent to participate
This study was approved by the Ethics Committee of Xuan Wu Hospital Capital Medical University; the review coding is [2015] 028. The study participants and their caregivers agreed to participate in this study, and all provided written informed consent.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Innovation Center for Neurological Disorders, Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, People’s Republic of China. 2Beijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, People’s Republic of China. 3Clinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing, People’s Republic of China. 4Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, People’s Republic of China. 5Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, People’s Republic of China. 6National Clinical Research Center for Geriatric Disorders, Beijing, People’s Republic of China. 7The Second People’s Hospital of Guiyang, Guizhou, People’s Republic of China.

Received: 22 December 2017 Accepted: 2 May 2018
Published online: 10 May 2018

References
1. Benson DF, Davis RJ, Snyder BD. Posterior cortical atrophy. Arch Neurol. 1984;41(7):789–93. http://www.ncbi.nlm.nih.gov/pubmed/6780033.
2. Crutch SJ, Lehmann M, Schott JM, Rabinovici GD, Rossor MN, Fox NC. Posterior cortical atrophy. Lancet Neurol. 2012;11(2):170–8. http://www.ncbi.nlm.nih.gov/pubmed/22265212.
3. Snowden JS, Stopford CL, Julien CL, Thompson JC, Davidson Y, Gibbons L, et al. Cognitive phenotypes in Alzheimer disease and genetic risk. Cortex. 2007;43(7):789–800. http://www.ncbi.nlm.nih.gov/pubmed/17941342.
4. Tang-Wai DF, Graf-Radford NR, Boeve BF, Dickson DW, Parisi JE, Crook R, et al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology. 2004;63(7):1168–74. http://www.ncbi.nlm.nih.gov/pubmed/15477533.
5. Renner JA, Burns JM, Hou CE, McKee DL Jr, Storandt M, Morris JC. Progressive posterior cortical dysfunction: a clinicopathologic series. Neurology. 2004;63(7):780–5. http://www.ncbi.nlm.nih.gov/pubmed/15477534.
6. Mendez MF, Ghajarian M, Peryman KM. Posterior cortical atrophy: clinical characteristics and differences compared to Alzheimer’s disease. Dement Geriatr Cogn Disord. 2002;14(1):33–40. http://www.ncbi.nlm.nih.gov/pubmed/12053130.
7. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the NG-2 criteria. Lancet Neurol. 2014;13(6):614–20. http://www.ncbi.nlm.nih.gov/pubmed/24849862.
8. Kaeser PF, Chikha J, Bournat FX. Visual signs and symptoms in patients with the visual variant of Alzheimer disease. BMC Ophthalmol. 2015;15:65. http://www.ncbi.nlm.nih.gov/pubmed/26212482.
9. Charles RJ, Hills AE. Posterior cortical atrophy: clinical presentation and cognitive deficits compared to Alzheimer’s disease. Behav Neurol. 2005;16(1):15–23. https://www.ncbi.nlm.nih.gov/pubmed/16082076.
10. McMonagle P, Deering F, Berliner Y, Kertesz A. The cognitive profile of posterior cortical atrophy. Neurology. 2006;66(3):331–8. https://www.ncbi.nlm.nih.gov/pubmed/16476930.
11. Kas A, de Souza LC, Sarni D, Bartolomeo P, Lacambles L, Kalafat M, et al. Neural correlates of cognitive impairment in posterior cortical atrophy. Brain. 2011;134(Pt 3):464–78. http://www.ncbi.nlm.nih.gov/pubmed/21478188.
12. Crutch SJ, Schott JM, Rabinovici GD, Boeve BF, Cappa SF, Dickenson BC, et al. Shining a light on posterior cortical atrophy. Alzheimers Dement. 2013; 9(4):463–5. https://www.ncbi.nlm.nih.gov/pubmed/23274153.
13. Fu L, Liu L, Zhang J, Xu B, Fan Y, Tian J. Comparison of dual-biomarker PIB-PET and dual-tracer PET in AD diagnosis. Eur Radiol. 2014;24(11):2800–9. http://www.ncbi.nlm.nih.gov/pubmed/25097125.
14. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98. https://www.ncbi.nlm.nih.gov/pubmed/1202204.
15. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9. https://www.ncbi.nlm.nih.gov/pubmed/15817019.
16. Morris JC. The clinical dementia rating (CDR). current version and scoring rules. Neurology. 1993;43(11):1442–4. http://www.ncbi.nlm.nih.gov/pubmed/2323972.
17. Maj M, D’Elia L, Satz P, Janssen R, Zaudig M, Uchiyama C, et al. Evaluation of two new neuropsychological tests designed to minimize cultural bias in the assessment of HIV-1 seropositive persons: a WHO study. Arch Clin Neuropsychol. 1993;8(2):123–35. http://www.ncbi.nlm.nih.gov/pubmed/14589870.
18. Kaplan EF, Goodglass H, Weintraub S. The Boston naming test. Philadelphia: Lea & Febiger; 1983.
19. Liberman J, Stewart W, Seines O, Gordon B. Rater agreement for the Rey-Osterrieth complex figure test. J Clin Psychol. 1994;50(4):615–24. https://www.ncbi.nlm.nih.gov/pubmed/7983212.
20. Wechsler D. The Wechsler adult intelligence scale-revised. New York: The Psychological Corporation; 1981.
21. Allen DN, Haderlie MM. Trail-Making Test. The Corin Encyclopedia of Psychology: John Wiley & Sons, Inc.; 2010.
22. Gao S, Chu Y, Shi S, Peng Y, Dai S, Wang Y, et al. Standardized aphasia battery of Chinese. Chin Ment Health J. 1992;6(3):125–8.
23. Yong KK, Rajdev K, Shakespeare TJ, Leff AP, Crutch SJ. Facilitating text reading in posterior cortical atrophy. Neurology. 2015;85(4):339–48. http://www.ncbi.nlm.nih.gov/pubmed/26138948.
24. Yong KK, Shakespeare TJ, Cash D, Henley SM, Warren JD, Crutch SJ. Context-specific effects of visual dysfunction on reading in posterior cortical atrophy. Cortex. 2014;57:92–106. http://www.ncbi.nlm.nih.gov/pubmed/24841985.
25. Gauthier L, Dehaut F, Joannette Y. The bells test: a quantitative and qualitative test for visual neglect. Int J Clin Neuropsychol. 1989;11(2):49–54. https://www.ncbi.nlm.nih.gov/pubmed/29326988.
26. Delta S, Sava J, Cuacor M, Spinnler H, Triviell C, Poppeleker-Gheni’s overlapping figures test: its sensitivity to age, and its clinical use. Arch Clin Neuropsychol. 1995; 10(5):31–34. http://www.ncbi.nlm.nih.gov/pubmed/8458806.
27. Navon D. Forest before trees: the precedence of global features in visual perception. Cogn Psychol. 1979;7(3):353–83. https://doi.org/10.1016/0010-0285(79)90012-3.
28. Goodglass H, Kaplan E. The assessment of aphasia and related disorders. 2nd ed. Philadelphia: Lea & Febiger; 1983. vii, 102, 31 p.
29. Singh TD, Josephs KA, Matchulka MM, Drubach DA, Apostolova LG, Lowe VL, et al. Clinical, FDG and amyloid PET imaging in posterior cortical atrophy. J Neurol. 2015;262(6):1483–92. http://www.ncbi.nlm.nih.gov/pubmed/25862483.
30. Migliaccio R, Gallea C, Kas A, Perlbarg V, Sarni D, Trotta L, et al. Functional connectivity of ventral and dorsal visual streams in posterior cortical atrophy. J Alzheimers Dis. 2016;51(4):119–30. http://www.ncbi.nlm.nih.gov/pubmed/26923019.
31. Trojano L, Gainotti G. Drawing Disorders in Alzheimer’s disease and other forms of dementia. J Alzheimers Dis. 2016;53(1):31–52. http://www.ncbi.nlm.nih.gov/pubmed/27104898.
32. Chechlacz M, Novick A, Rotshtein P, Bickerton WL, Humphreys GW, Demeyere N. The neural substrates of drawing: a voxel-basedmorphometry analysis of constructive, hierarchical, and spatial representation deficits. J Cogn Neurosci. 2014;26(2):2270–15. http://www.ncbi.nlm.nih.gov/pubmed/24893744.
33. Ardila A, Rosselli M. Spatial agraphia. Brain Cogn. 1993;22(2):137–47. http://www.ncbi.nlm.nih.gov/pubmed/8173568.
34. Ardila A, Rosselli M, Ariusa LF, Kujis RD. Alexia and agraphia in posterior cortical atrophy. Neuropsych Neuropsychol Behav Neurol. 1997;10(6):511. https://www.ncbi.nlm.nih.gov/pubmed/9118197.
35. Croisile B, Trillet M, Hilbert O, Cinotti L, Le Bars D, Mauguiere F, et al. Visuo-constructional disorders and alexia-agraphia associated with posterior cortical atrophy. Rev Neurol. 1991;147(2):138–43. http://www.ncbi.nlm.nih.gov/pubmed/20428147.
36. Rapcsak SZ, Arthur SA, Rubens AB. Lexical agraphia from focal lesion of the left precentral gyrus. Neurology. 1988;38(7):1119–23. http://www.ncbi.nlm.nih.gov/pubmed/3386842
37. Law SP, Or B. A case study of acquired dyslexia and dysgraphia in Cantonese: evidence for nonsemantic pathways for reading and writing Chinese. Cogn Neuropsychol. 2001;18(8):729–48. http://www.ncbi.nlm.nih.gov/pubmed/20945235
38. Morin O. Spontaneous emergence of legibility in writing systems: the case of orientation anisotropy. Cogn Sci. 2017; http://www.ncbi.nlm.nih.gov/pubmed/29023934
39. Warrington EK, Shallice T. Word-form dyslexia. Brain. 1980;103(1):99–112. http://www.ncbi.nlm.nih.gov/pubmed/6244876
40. Hillis AE, Caramazza A. Cognitive and neural mechanisms underlying visual and semantic processing: implications from “optic aphasia”. J Cogn Neurosci. 1995;7(4):457–78. http://www.ncbi.nlm.nih.gov/pubmed/23961905
41. Perfetti C, Liu Y. Orthography to phonology and meaning: comparisons across and within writing systems. Read Writ. 2005;18:193–210. https://link.springer.com/article/10.1007/s11145-004-2344-y
42. Mendez MF, Shapira JS, Clark DG. "Apperceptive" alexia in posterior cortical atrophy. Cortex. 2007;43(2):264–70. http://www.ncbi.nlm.nih.gov/pubmed/17405672
43. Xu GF, Jing J. Major achievements in relation to dyslexia in Chinese characters. Chin Med J. 2008;121(17):1736–40. http://www.ncbi.nlm.nih.gov/pubmed/19024108
44. Ahmed S, Baker I, Husain M, Thompson S, Kipps C, Hornberger M, et al. Memory impairment at initial clinical presentation in posterior cortical atrophy. J Alzheimers Dis. 2016;52(4):1245–50. https://www.ncbi.nlm.nih.gov/pubmed/27128371